CASI Pharmaceuticals, Inc.(CASIF)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $43.1M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
CASIF Stock Analysis & AI Quality Score
AI stock analysis and institutional research for CASI Pharmaceuticals, Inc. (CASIF), a Healthcare sector company. CASIF is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $43.1m in revenue. Based on the latest XBRL financial filings (FY 2025), CASI Pharmaceuticals, Inc. reports quarterly revenue of $20.7M, net income of $-48.1M, free cash flow of $-20.8M. Top institutional holders of CASIF by reported 13-F value include VR Adviser,, NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO, Woodline Partners, based on the most recent SEC filings. CASIF trades on the Nasdaq exchange and files with the SEC under CIK 1962738. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CASIF daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CASI Pharmaceuticals, Inc. directly from SEC EDGAR.
Revenue
FY 2025
$20.7M
Net Income
FY 2025
$-48.1M
Free Cash Flow
FY 2025
$-20.8M
AI Insight: CASIF Financial Trends
CASI's equity turned negative in Q4 2025 as debt remained elevated, signaling severe balance-sheet distress.
• Equity collapsed from $2M (Q4 2024) to −$37M (Q4 2025), indicating liabilities now exceed assets.
• Total debt fluctuated between $19M–$37M; currently $19M in Q4 2025, but equity erosion leaves minimal cushion.
⚠ Negative shareholder equity signals insolvency risk; debt restructuring or capital raise likely required.
⚠ No revenue, net income, or cash-flow data disclosed; financial opacity compounds leverage concerns.
AI Insight: CASIF Ratio Trends
Debt-to-equity ratio surged to 20.14 in Q4 2024, signaling acute leverage stress in a cash-constrained biotech.
• D/E jumped from 0.78 in Q4 2023 to 20.14 in Q4 2024 — a 25-fold increase in one year.
⚠ Extreme leverage spike suggests debt issuance or equity dilution. Balance sheet stability is critical for pipeline funding.
Get alerted when CASIF's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for CASI Pharmaceuticals, Inc. including:
Top Institutional Holders of CASIF
VR Adviser, LLC
$839.2K987,259 shNORTHWESTERN MUTUAL WEALTH MANAGEMENT CO
$145.6K5,226 shWoodline Partners LP
$113.4K133,406 shRENAISSANCE TECHNOLOGIES LLC
$36.6K43,100 shTWO SIGMA INVESTMENTS, LP
$20.2K23,787 shBANK OF AMERICA CORP /DE/
$16.9K19,869 shGEODE CAPITAL MANAGEMENT, LLC
$16.0K18,808 shCITADEL ADVISORS LLC
$11.9K14,045 shROYAL BANK OF CANADA
$8.0K9,950 shGROUP ONE TRADING, L.P.
$935.001,100 sh
| Fund | Value | Shares |
|---|---|---|
| VR Adviser, LLC | $839.2K | 987,259 |
| NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | $145.6K | 5,226 |
| Woodline Partners LP | $113.4K | 133,406 |
| RENAISSANCE TECHNOLOGIES LLC | $36.6K | 43,100 |
| TWO SIGMA INVESTMENTS, LP | $20.2K | 23,787 |
| BANK OF AMERICA CORP /DE/ | $16.9K | 19,869 |
| GEODE CAPITAL MANAGEMENT, LLC | $16.0K | 18,808 |
| CITADEL ADVISORS LLC | $11.9K | 14,045 |
| ROYAL BANK OF CANADA | $8.0K | 9,950 |
| GROUP ONE TRADING, L.P. | $935.00 | 1,100 |
More Healthcare Companies
View all Healthcare →Put CASIF on your watchlist
Track score changes the day CASI Pharmaceuticals, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is CASIF a good stock to buy?
13F Pro's AI-powered analysis of CASI Pharmaceuticals, Inc. (CASIF) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CASIF are available on the CASIF stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own CASIF?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CASIF. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of CASI Pharmaceuticals, Inc.'s investment landscape.